VivoSim Labs (FRA:4OR) 3-Year Share Buyback Ratio: -37.80% (As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
38 GF Score
Price €3.49
GF Value €10.53
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs 3-Year Share Buyback Ratio?

VivoSim Labs FRA:4OR 38 3-Year Share Buyback Ratio is -37.80 as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €10.53. The stock has 4 warning signs investors should review. Among 1,192 Biotechnology companies, VivoSim Labs ranks worse than 78.61% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. VivoSim Labs's current 3-Year Share Buyback Ratio was -37.80%.

The historical rank and industry rank for VivoSim Labs's 3-Year Share Buyback Ratio or its related term are showing as below:

FRA:4OR' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -37.8   Med: -10.3   Max: -4.3
Current: -37.8

During the past 13 years, VivoSim Labs's highest 3-Year Share Buyback Ratio was -4.30%. The lowest was -37.80%. And the median was -10.30%.

FRA:4OR's 3-Year Share Buyback Ratio is ranked worse than
78.61% of 1192 companies
in the Biotechnology industry
Industry Median: -11.85 vs FRA:4OR: -37.80

VivoSim Labs (FRA:4OR) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


VivoSim Labs 3-Year Share Buyback Ratio Related Terms


FRA:4OR vs SLXN, CDT, CLDI: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, VivoSim Labs's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's 3-Year Share Buyback Ratio falls into.


FRA:4OR
38GF Score
VivoSim Labs Inc FRA:4OR
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -37.80 mean?
VivoSim Labs (FRA:4OR) has a 3-Year Share Buyback Ratio of -37.80 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #937 out of 1192 companies in the Biotechnology industry, placing it in the top 78.6%.
Is VivoSim Labs' 3-Year Share Buyback Ratio too high?
VivoSim Labs' current 3-Year Share Buyback Ratio is -37.80. Based on the distribution chart, VivoSim Labs ranks #937 out of 1192 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' 3-Year Share Buyback Ratio compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #937 out of 1192 companies for 3-Year Share Buyback Ratio. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for VivoSim Labs and its competitors. VivoSim Labs's current 3-Year Share Buyback Ratio is -37.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current 3-Year Share Buyback Ratio of -37.80. The stock's GF Value™ is €10.53, compared to a current price of €3.49 — trading 66.8% below its estimated fair value. The current 3-Year Share Buyback Ratio is -37.80. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current 3-Year Share Buyback Ratio is -37.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 66.8% below its estimated GF Value™ of €10.53.

Key valuation signals for FRA:4OR:

  • 3-Year Share Buyback Ratio: -37.80
  • GF Value™: €10.53 vs. price of €3.49 (66.8% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score

Get the complete analysis for FRA:4OR

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€10.53
GF Value